Abstract The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the
researchers to strive to develop drugs or vaccines to prevent or halt the progression of this …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most
of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe …

Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza
drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a …

Abstract Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent
that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA …

Background Repurposing broad-spectrum antivirals is an immediate treatment opportunity
for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for …

Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in
Japan to treat pandemic influenza virus infections. The drug is converted intracellularly into …

Eight different compounds, all nucleoside analogues, could presently be considered as
potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic …

Sir, A novel coronavirus, SARS-CoV-2, emerged in December 2019 in Wuhan, China, which
is spreading far more rapidly than its predecessors, having already infected millions of …

The present work describes development of rapid, robust, sensitive and green
spectrofluorimetric method for determination of favipiravir (FAV). Different factors affecting …